WNT4 and thymoma: Considering that the most aggressive TETs, B3 thymomas, and TCs showed combined increased expression of WNT4, its non-canonical frizzled receptor 6 (FZD6) (41, 44), and downstream non-canonical WNT/JNK activity, TETs appear as promising candidates for trials testing novel inhibitors of WNT and JNK (52).